Mirae Asset Global Investments Co. Ltd. Reduces Stock Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Mirae Asset Global Investments Co. Ltd. cut its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 12.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 9,130 shares of the biopharmaceutical company’s stock after selling 1,298 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in Alnylam Pharmaceuticals were worth $2,164,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of ALNY. Huntington National Bank raised its position in shares of Alnylam Pharmaceuticals by 91.8% during the 3rd quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 45 shares during the period. Hollencrest Capital Management purchased a new position in Alnylam Pharmaceuticals in the third quarter worth approximately $29,000. R Squared Ltd acquired a new stake in Alnylam Pharmaceuticals during the fourth quarter worth $33,000. Washington Trust Advisors Inc. purchased a new stake in Alnylam Pharmaceuticals in the third quarter valued at $42,000. Finally, True Wealth Design LLC lifted its stake in shares of Alnylam Pharmaceuticals by 15,300.0% in the 3rd quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 153 shares during the last quarter. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Alnylam Pharmaceuticals

In other news, EVP Tolga Tanguler sold 1,469 shares of the business’s stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total value of $368,689.62. Following the completion of the sale, the executive vice president now directly owns 13,191 shares of the company’s stock, valued at approximately $3,310,677.18. The trade was a 10.02 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CMO Pushkal Garg sold 1,682 shares of the firm’s stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total value of $422,148.36. Following the transaction, the chief marketing officer now owns 17,457 shares in the company, valued at $4,381,357.86. This represents a 8.79 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 73,964 shares of company stock worth $20,622,925. 1.50% of the stock is currently owned by insiders.

Analysts Set New Price Targets

ALNY has been the subject of a number of recent analyst reports. Raymond James raised their price objective on Alnylam Pharmaceuticals from $275.00 to $298.00 and gave the stock an “outperform” rating in a research report on Friday, November 1st. Needham & Company LLC reissued a “buy” rating and issued a $320.00 price target on shares of Alnylam Pharmaceuticals in a research note on Monday, January 13th. Chardan Capital restated a “buy” rating and issued a $300.00 price objective on shares of Alnylam Pharmaceuticals in a report on Friday, November 1st. Bank of America lifted their target price on shares of Alnylam Pharmaceuticals from $307.00 to $314.00 and gave the company a “buy” rating in a report on Monday, October 14th. Finally, Sanford C. Bernstein decreased their price target on Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating on the stock in a research note on Tuesday, January 7th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and nineteen have given a buy rating to the company’s stock. Based on data from MarketBeat, Alnylam Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $298.61.

Alnylam Pharmaceuticals Price Performance

ALNY stock opened at $276.19 on Monday. The business has a 50 day moving average price of $252.78 and a 200 day moving average price of $262.47. The company has a quick ratio of 2.69, a current ratio of 2.75 and a debt-to-equity ratio of 31.64. The stock has a market cap of $35.62 billion, a price-to-earnings ratio of -105.42 and a beta of 0.35. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $141.98 and a fifty-two week high of $304.39.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.